AU632495B2 - Method of producing proteins with fviii activity and/or fviii derivatives - Google Patents

Method of producing proteins with fviii activity and/or fviii derivatives Download PDF

Info

Publication number
AU632495B2
AU632495B2 AU38755/89A AU3875589A AU632495B2 AU 632495 B2 AU632495 B2 AU 632495B2 AU 38755/89 A AU38755/89 A AU 38755/89A AU 3875589 A AU3875589 A AU 3875589A AU 632495 B2 AU632495 B2 AU 632495B2
Authority
AU
Australia
Prior art keywords
fviii
cells
temperature
activity
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU38755/89A
Other versions
AU3875589A (en
Inventor
Ole Nordfang
Poul Baad Rasmussen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to AU38755/89A priority Critical patent/AU632495B2/en
Priority claimed from PCT/DK1989/000168 external-priority patent/WO1991000347A1/en
Publication of AU3875589A publication Critical patent/AU3875589A/en
Application granted granted Critical
Publication of AU632495B2 publication Critical patent/AU632495B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Description

~~ij OPI DATE 17/01/91 PCT AOJP DATE 07/03/91 APPLN. ID 38755 89 PCT NUMBER PCT/DK89/00168
INTERNATIONAL.
(PCT)
(51) International Patent Classification 4 C12N 15/00, C12P 21/00 (11) International P-blication Number: Al (43) International Publication Date: WO 91/00347 10 January 1991 (10.01.91) (21) International Application Number: (22) International Filing Date: PCT/DK89/00168 4 July 1989 (04.07.89) (71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo All, DK-2880 Bagsvard (DK).
(72) iventors; and Inventors/Applicants (for US only) RASMUSSEN, Poul, Baad [DK/DK]; Aurehojvej 19, DK-2900 Hellerup NORDFANG, Ole [DK/DK]; Selskovvej 6, DK- 3400 Hillerod (DK).
(74) Common Representative: NOVO NORDISK A/S; Patent Department, Novo Alle, DK-2880 Bagsvard (DK).
(81) Desl -te btate T (l tropipat AU, BB, BE peaL atant BF(API_ pten G, BJ (OAPI tet), C A ten G I patent), CH (LlpeRpatll CM PAPTpatent), DE (European patent)*, DK, FI, FR (European patent), GA (OAPI patent), GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US.
Published With international search report.
(54) Title: METHOD OF PRODUCING PROTEINS WITH FVIII ACTIVITY AND/OR FVIII DERIVATIVES (57) Abstract In a process for producing proteins with FVIII activity and FVIII derivatives by in vitro culturing of mammalian cells, the culturing is carried out at temperatures below 32 0 C and the culturing times used are below 24 hours.
See back of page I WO 91/00347 PCT/DK89/00168 1 METHOD OF PRODUCING PROTEINS WITH FVIII ACTIVITY AND/OR FVIII DERIVATIVES The present invention relates to a method of producing proteins with FVIII activity and/or FVIII derivatives by in vitro culturing of mammalian cells.
The bleeding disorder Hemophilia A is caused by the absence of Factor VIII (FVIII). FVIII is a glycoprotein which can be isolated from blood plasma (US no. 4,650,858). Purified FVIII is used in the treatment of Hemophilia A. By the use of gene -echnology it is possible to synthesize FVIII (EPO 160,457, WO 85/01961, US 570,062). The amount of FVIII, which can be produced in mammalian cells is rather low compared with other human proteins. The amount of protein can be increased if truncated variants of FVIII are biosynthesized (WO 86/06101, DK 3442/87), or if the two subunits (FVIII heavy chain and FVIII light chain) are coproduced (US 822,989). It is also possible in vitro to assemble active FVIII from separately produced subunits (DK 2957/86). The above-mentioned forms of FVIII all have the characteristics of human FVIII: activity in bioassays, activatable by thrombin, and biological activity in hemophilia dogs.
Mammals are in part characterized by the ability to keep a constant body temperature near 37°C. Therefore mammalian cells in general are grown in vitro at 37°C. FVIII circulates in the body at that temperature, and by culturing in serum containing medium (which mimic body fluid) one may expect that FVIII has optimal stability.
FVIII produced in serum free medium is rather unstable, but nevertheless it is attractive to emit serum from the medium, and WO 87/04187 shows that FVIII ca, be stabilized in serum free medium by addition of the carrier protein von Willebrand Factor (vWF). DK 3594/87 shows that FVIII ii WO 91/00347 PCT/DK89/00168 2 can also be stabilized in serum free medium by addition of lipoproteins. These stabilizing agents exhibit no pronounced effect in serum containing medium.
It has surprisingly been found that by culturing mammalian cells at a temperature below 37"C, more precisely below 33 C, the yields of truncated FVIII variants and of FVIII derived subunits (especialy FVIII heavy chain) are increased drastically, both in serum containing and in serum free medium.
It is preferred to carry out the culturing at a temperature from 10 to 32"C, more preferred at a temperature from to 30°C, and most preferred at 27"C.
Furthermore it has surprisingly appeared that the yields are raised by shortening the medium residence time below the usual 24-72 hours, which normally gives the optimal yields from mammalian cells.
It is preferred to use a medium residence time of 30 hours or below, more preferred 24 hours or below, even more preferred 10 hours or below, and most preferred below 4 hours.
The combined effect of low growth temperature and short medium residence time is especially pronounced in the case of FVIII heavy chain for which the yield can be raised times.
The increased yield of FVIII heavy chain (HC) at low temperature and short medium residence time can be related to unstability of the product at normal growth conditons.
Table 1 shows that FVIII heavy chain at 37 C loses the ability to combine with FVIII light chain. Fig. 1 shows that FVIII heavy chain form aggregates at 37*C. These
-C
WO 91/00347 PCT/DK89/00168 aggregates can be dissolved upon reduction. Truncated variants of FVIII may behave like FVIII-HC and form aggregates at high temperature. However, the increased yield at low temperature may also be caused by other factors than a decrease in aggregation. For example a greater resistance against proteolytic degradation might be important.
The preferred host cells will include mammalian cells such as CHO cells, COS-7 monkey cells, melanoma cell lines such as Bowes cells, mouse L-929 cells 3T3 lines, Balb-c or NIH mice, BHE or HAK hamster cell lines and the like.
The examples show that the yields of truncated FVIII variants, FVIII heavy chain, FVIII light chain and FVIII obtained from cells cotransfected with plasmids encoding each of the two subunits are increased at low temperature.
Table 1 Lane Incubation of Treatment for Combination FVIII-HC sample SDS-PAGE capacity for (Fig. 1) diluted sample, FVIII:C mU/ml 0 h, 37"C reduced 6 4 h, 37"C 7 26 h, 37C 8 0 h, 37°C unreduced 10.4 9 4 h, 37°C 26 h, 37°C 11 26 h, 22°C unreduced 8.3 12 4 h, 22°C 8.6 13 0 h, 22°C 10.6 14 26 h, 22°C reduced 4 h, 22°C 16 0 h, 22C 19 MW markers
-I
U C WO 91/00347 PCT/DK89/00168 4 Plasma derived FVIII-HC (300 U/ml) was diluted 4 fold in 0.05% BSA, 50 mM tris, 0.1 M Nacl, 0.02% NaN 3 150 IM 2-ME, pH 7.4 and incubated at 220C and 37°C. At t=0, 4, 24 h samples were freezed at -80°C. The samples were thawn and analysed (unboiled) reduced and unreduced in Western blot Furthermore, the samples were diluted 300 fold and tested for combination with FVIII-LC (WO 88/00210).
The invention is further explained with reference to the drawings in which Fig. 1 shows Western blot of FVIII-HC incubated at 22*C and 37°C (samples are the same as in Table 1).
D'crVi to+ -I rv of l acmi dC le p Plasmid pPR49 Description cDNA encoding a Factor VIII variant, in which 880 amino acids are deleted in the B-region (the variant is identical to the one encoded by the pLA-2 plasmid in PCT Patent Application, Publication no. WO 86/06101), has been inserted into the expression vector pSV7d (Truett et al., 1985, DNA 4; 333-349).
cDNA encoding a Factor VIII variant, in which Arg-740 has been fused directly to Ser-1690, has been inserted into pSV7d.
cDNA encoding the Factor VIII derived 92 kD peptide (heavy chain) has been inserted into pSV7d.
cDNA encoding the Factor VIII derived 80 kD peptide (light chain) has been inserted into pSV7d.
pSVF8-92E pSVF3-80K IL 1 WO 91/00347 PCT/DK89/00168 Example 1 The effect of growth temperature on the yield of proteins with Factor VIII activity The expression plasmids pPR49 and pPR60 were transfected to COS-7 monkey cells (Gluzman, 1981, Cell 23; 175-182) by usage of the calcium phosphate technique (Graham and van der Eb, 1973, Virology 52; 456-467) with the modifications described in: DNA Cloning, a Practical Approach, Vol.
I+II/IRL Press. (Each plasmid was totally transfected to eight 5 cm's dishes: 2 times 2 dishes determined for expression at 37°C and 27*C, respectively, in serum containing medium and the same number of dishes in serum free medium). 16 hours post transfection the media were changed; half the dishes were shifted to serum free medium. 40 hours post transfection the media were changed and half the dishes were transferred to a 27*C incubator.
After additional 24 hours the media were harvested and the Factor VIII activity was determined by usage of the Kabi coatest chromogenic assay method. The results are listed in Table 2: Table 2 Plasmid Temp. Chromogenic activity (mU/ml/day) serum serum pPR49 37 1023 277 37 1028 248 27 1862 1051 27 1695 977 37 89 >138 37 104 >138 27 336 387 27 322 401 i WO 91/00347 PCT/DK89/00168 6 Example 2 The combined effect of low growth temperature and short medium residence time on the yield of Factor VIII heavy chain from a CHO cell line The CHO (Chinese Hamster Ovary) cell line DUKX-B11 Urlaub and Chasin, 1980, PNAS 77; 4216-4220), which is mutated in the dihydrofolate reductase gene, was co-transfected with the plasmids pSVF8-92E and pSVF8-80K plus a plasmid encoding the dihydrofolate reductase. (These cotransfections are described in US Patent Application No.
82,989), Hereby a clone (10C2D2) was isolated, characterized by producing 10 fold more heavy chain (HC) than light chain (LC) when it is grown at 37°C. When 10C2D2 is grown at 27*C the yield of HC is raised dramatically seen in relation to the yield of LC (see Table 3).
Table 3 Temp. Culturing Vol.med./T-80 flask HC:Ag* LC:Ag* time (ml) (U/ml) (U/ml) (hours) 37 24 10 3.2 0.36 27 24 10 18.4 0.28
B
i HC:Ag and LC:Ag were measured in specific immuno assays (Nordfang et al., 1988, Br.J.Haematol. 307-312; Nordfang et al., 1985, Thromb.Haemostas, 53:346-350).
By shortening the medium residence time to only 2 hours a greater yield of HC per day is achieved (Table 4): WO 91/00347 PCT/DK89/00168 7 Table 4 Temp. Culturing Vol.med./T-80 flask HC:Ag HC:Ag time (ml) (U/ml) (U/ml/ (hours) day) 37 24 10 3.2 3.2 27 24 10 18.4 18.4 27 2 10 7.5 27 2 3 24.0 288 Example 3 Production of FVIII:HC in Opticell Bioreactor at 28-30 0
C
by 10C2D2 In the Opticell bioreactor the cells are cultured on a ceramic matrix, the Opticore, and the culture media is circulated through the Opticore. The oxygen content, pH, medium feed and harvest are all measured and controlled by the system.
The average medium circulation time was 5 hours (150 ml per hour with a volume in the reservoir Opticore of 750 ml).
The harvest was collected at 5°C and frozen every 24 h at The cells were cultured at 37°C until near confluent (measured by the oxygen comsumption rate) and the temperature was lowered to 28-30"C for production of
FVIII:HC.
The cells were kept at the production temperature for 1000 hours. The oxygen comsumption rate decreased in a couple of hours when the temperature was lowered from 37*C to and from 30*C to 28*C, but each time the oxygen comsumption rate gradually increased again. Thus the cells WO 91/00347 PCT/DK89/00168 could be maintained at the lower temperature even for longer than the 1000 hours.
In Table 5 the medium composition and feed/harvest volumes as well as the FVIII:HC levels for some of the harvest samples are shown.
WO 91/00347 Table Examp The prote Table Hours after Medium Feed/Har- FVIII:HC FVIII:HC temperature vest U/mi U/day shift to ml/h 28-30*C DMEH 1% ITS 408 2% FCS 100 15.1 36240 432 2% FCS 150 10.9 39240 456 2% NCS 150 11.0 39600 The D Proc.
transf Factox cells cell heavy Example 4 The effect of low growth temperature on yield of Factor VIII liaht chain from COS-7 monkey cells
I~
An expression plasmid designated pPR77 encoding Factor VIII light chain was transfected to COS-7 cells in the same manner as described in Example 1. The plasmid was transfected to four 5 cm dishes: two times two dishes determined for expression at 37*C and 27*C, respectively.
The media (DMEM 10% FCS) were changed 16 and 40 hours post transfection (at 40 hours half the dishes were transferred to a 27'C incubator). After additional 24 hours the media were harvested. The content of Factor VIII light chain was determined as described in Example 2. The results are given in Table 6.
30 P. Berc 341, contai Cells medium 35 were s conflue 0.1 incubat collect WO 91/00347 PCT/DK89/00168 9 Table 6 Temp. LC:Ag (U/ml/day) 37 0.33 37 0.30 27 1.25 27 0.85 Example The effect of low growth temperature on the yield of protein-complex with Factor VIII activity from CHO cells transfected with plasmids encodin each of the two subunits of Factor VIII: the heavy chain and the light chain The DHFR(-) CHO cell line DG44 (cf. G. Urlaub et al., Proc.Natl.Sci., USA 77; 4216-4220, 1980) was first transfected with a plasmid encoding the light chain of Factor VIII and the dhfr gene. By selection of DHFR(+) cells a stable light-chain producer was isolated. This new cell line was co-transfected with a plasmid encoding the heavy chain of Factor VIII (and the dhfr gene) and a plasmid encoding the neo gene (pSV2neo; P.J. Southern and P. Berg, Journal of Molecular and Applied Genetics 1; 327- 341, 1982). Transfectants were isolated in medium containing 700 pg Geneticin (G418 Sulphate, Gibco) per ml.
Cells from the primary pool were propagated directly into medium containing 0.1 iM MTX. Cells isolated in this way were seeded into two T-80 flasks, called A and B. At confluence the media (DMEM 10% DFCS 700 gg Geneticin/ml 0.1 pM MTX) were changed (10 ml) and the flasks were incubated 24 hours at 37°C whereafter media samples were collected. The media were renewed and the B flask was WO 91/00347 PCT/DK89/00168 transferred to a 27 0 C incubator. Again the flasks were incubated for 24 hours followed by collection of media samples and renewing of media. This procedure was repeated for another two days (the A flask still at 37"C and the B flask still at 27'C). The Factor VIII activity was determined by the Kabi coatest chromogenic assay method.
The results are given in Table 7.
Table 7 Day Temp. Chromogenic activity (U/ml/day) Flask A: 1 37 0.42 2 37 0.77 3 37 0.84 4 37 Flask B: 1 37 0.50 2 27 1.20 3 27 1.72 4 27 3.2

Claims (6)

1. A method for producing recombinant proteins with FVIII activity and/or FVIII derivativ;, by in vitro culturing of mammalian cells, said culturing being carried out at a temperature below 33 0 C.
2. A method as claimed in Claim 1, wherein the temperature is from 10 to 32 0 C.
3. A method as claimed in Claim 2, wherein the temperature is from 25 to 30 0 C.
4. A method as claimed in Claim 3, wherein the temperature is 27 0 C. A method as claimed in any of Claims 1-4, wherein the FVIII derivative produced is the 92.5 kD fragment or the "Heavy Chain". S 15 6. A method as claimed in any of Claims 1-4, wherein the FVIII derivative produced is the 80 kD fragment or the "Light Chain".
7. A method as claimed in any of Claims 1-4, wherein the resulting product is a protein-complex with XVIII 20 activity obtained from cells transfected with plasitrc encoding each of the two subunits of FVIII: the heavy S chain and the light chain. 11''
8. A method as claimed in any of Claims 1-7, wherein the mammalian cells used are COS cells, CHO cells or BHK cells. 7M /2
AU38755/89A 1989-07-04 1989-07-04 Method of producing proteins with fviii activity and/or fviii derivatives Expired AU632495B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU38755/89A AU632495B2 (en) 1989-07-04 1989-07-04 Method of producing proteins with fviii activity and/or fviii derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU38755/89A AU632495B2 (en) 1989-07-04 1989-07-04 Method of producing proteins with fviii activity and/or fviii derivatives
PCT/DK1989/000168 WO1991000347A1 (en) 1989-07-04 1989-07-04 Method of producing proteins with fviii activity and/or fviii derivatives

Publications (2)

Publication Number Publication Date
AU3875589A AU3875589A (en) 1991-01-17
AU632495B2 true AU632495B2 (en) 1993-01-07

Family

ID=3725730

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38755/89A Expired AU632495B2 (en) 1989-07-04 1989-07-04 Method of producing proteins with fviii activity and/or fviii derivatives

Country Status (1)

Country Link
AU (1) AU632495B2 (en)

Also Published As

Publication number Publication date
AU3875589A (en) 1991-01-17

Similar Documents

Publication Publication Date Title
EP0506757B2 (en) A recombinant human factor viii derivative
US6358703B1 (en) Expression system for factor VIII
RU2477318C2 (en) Improved titre of polypeptide of factor viii in cell cultures
US4868112A (en) Novel procoagulant proteins
KR950012804B1 (en) Method for producing recombinaut human factor ñ¿:c
WO1988003558A1 (en) Eucaryotic expression system
EP0480923B1 (en) Method of producing proteins with fviii activity and/or fviii derivatives
AU632495B2 (en) Method of producing proteins with fviii activity and/or fviii derivatives
US5610033A (en) Method of producing proteins with FVIII activity and/or FVIII derivatives
EP1673391B1 (en) MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
CA2058785C (en) Method of producing proteins with fviii activity and/or fviii derivatives
DK168713B1 (en) Process for preparing proteins which possess FVIII (factor VIII) activity, and/or FVIII derivatives
CA2149212A1 (en) Improved recombinant production of proteins having factor viii:c activity
MXPA01005667A (en) Expression system for factor viii